ARVN ARVINAS, INC.
Price Chart
Executive Summary
Arvinas announced positive Phase 1 clinical trial data for ARV-102, showing greater than 50% degradation of LRRK2 in cerebrospinal fluid of Parkinson's disease patients, with the drug well-tolerated across all doses. The company plans to initiate a Phase 1b trial in progressive supranuclear palsy in Q2 2026, with potential for a registrational trial in late 2026.
Actionable Insight
Monitor upcoming Phase 1b trial initiation in progressive supranuclear palsy and watch for further clinical data that could validate ARV-102's efficacy in neurodegenerative diseases.
Key Facts
- ARV-102 demonstrated >50% LRRK2 degradation in CSF at all doses by day 14, maintained through day 28
- Multiple oral doses of ARV-102 (20mg, 40mg, 80mg) were well tolerated with no serious adverse events
- Data presented at AD/PD 2026 conference in Copenhagen
- Company plans to initiate Phase 1b trial in progressive supranuclear palsy in Q2 2026
- Potential to initiate a registrational trial in late 2026
Financial Impact
No immediate financial impact, but positive clinical data increases the probability of future revenue from ARV-102
Risk Factors
- Phase 1 success does not guarantee success in later-stage trials
- Regulatory approval is still pending and not guaranteed
- Competitors may have similar therapies in development
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-019026 |
| Document: arv-102datapresentationp.htm | 0001628280-26-019026 |
| Document: 0001628280-26-019026-index-headers.html | 0001628280-26-019026 |
| Document: 0001628280-26-019026.txt | 0001628280-26-019026 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
7d ago
|
8-K
| $7.70 $7.74 | ▼ −0.52% | ▼ −0.12% | $7.15 (+7.14%) |
|
May 12, 2026
28d ago
|
8-K
| $9.57 $9.87 | ▲ +3.13% | ▲ +2.56% | $7.15 (−25.29%) |
|
May 12, 2026
28d ago
|
8-K
| $9.57 $9.87 | ▲ +3.13% | ▲ +2.56% | $7.15 (−25.29%) |
|
May 12, 2026
28d ago
|
Press Release
| $9.57 $9.87 | ▼ −3.13% | ▼ −2.56% | $7.15 (+25.29%) |
|
May 8, 2026
4w ago
|
144
| $9.66 $9.57 | ▼ −0.93% | ▼ −0.80% | $7.15 (−25.98%) |
|
May 8, 2026
4w ago
|
144
| $9.66 $9.57 | ▼ −0.93% | ▼ −0.80% | $7.15 (−25.98%) |
|
May 5, 2026
5w ago
|
Press Release
| $10.61 $10.26 | ▲ +3.30% | ▲ +4.68% | $7.15 (+32.61%) |
|
May 1, 2026
5w ago
|
8-K
| $10.51 $10.78 | ▲ +2.57% | ▲ +2.91% | $7.15 (−31.97%) |
|
May 1, 2026
5w ago
|
Press Release
| $10.51 $10.78 | ▲ +2.57% | ▲ +2.91% | $7.15 (−31.97%) |
|
Apr 29, 2026
5w ago
|
DEFA14A
| $9.82 $9.90 | ▲ +0.81% | ▼ −0.21% | $7.15 (−27.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access